Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction (Q34487487)

2 August 2017

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction (English)

1 reference

transthyretin amyloidosis

2 August 2017

0 references

1 reference

1 reference

Heart failure with preserved ejection fraction

1 reference

based on heuristic

inferred from title

author

Maria Gallego-Delgado

object named as

Maria Gallego-Delgado

2

0 references

Enrique Lara-Pezzi

object named as

Enrique Lara-Pezzi

9

0 references

author name string

Esther González-López

1

1 reference

2 August 2017

Gonzalo Guzzo-Merello

3

1 reference

2 August 2017

F Javier de Haro-Del Moral

4

1 reference

2 August 2017

Marta Cobo-Marcos

5

1 reference

2 August 2017

Carolina Robles

6

1 reference

2 August 2017

Belén Bornstein

7

1 reference

2 August 2017

Clara Salas

8

1 reference

2 August 2017

Luis Alonso-Pulpon

10

1 reference

2 August 2017

Pablo Garcia-Pavia

11

1 reference

2 August 2017

28 July 2015

1 reference

2 August 2017

European Heart Journal

1 reference

2 August 2017

36

1 reference

2 August 2017

2585-2594

1 reference

2 August 2017

38

1 reference

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

2 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Heart failure with preserved ejection fraction: a clinical dilemma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Developing therapies for heart failure with preserved ejection fraction: current state and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Transthyretin (TTR) cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Senile systemic amyloidosis: clinical features at presentation and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

How to image cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Poor R wave progression in the precordial leads: clinical implications for the diagnosis of myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Echocardiographic diagnosis of left ventricular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardio

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHV338

21 January 2018

Identifiers

DOI

10.1093/EURHEARTJ/EHV338

1 reference

2 August 2017

1 reference